CG Oncology Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
61
- Stock Symbol
-
CGON
- Share Price
-
$29.08
- (As of Friday Closing)
CG Oncology General Information
Description
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Contact Information
Website
www.cgoncology.comCorporate Office
- 400 Spectrum Center Drive
- Suite 2040
- Irvine, CA 92618
- United States
Corporate Office
- 400 Spectrum Center Drive
- Suite 2040
- Irvine, CA 92618
- United States
CG Oncology Timeline
CG Oncology Stock Performance
As of 17-Jan-2025, CG Oncology’s stock price is $29.08. Its current market cap is $2.21B with 67.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $29.08 | $29.10 | $25.77 - $50.23 | $2.21B | 67.6M | 663K | -$15.53 |
CG Oncology Financials Summary
As of 30-Sep-2024, CG Oncology has a trailing 12-month revenue of $684K.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,978,291 | |||
| Revenue | 684 | 204 | 191 | 10,358 |
| EBITDA | (95,943) | (55,494) | (35,427) | (12,378) |
| Net Income | (72,796) | (48,607) | (35,443) | (12,839) |
| Total Assets | 552,471 | 199,301 | 147,747 | 58,692 |
| Total Debt | 296 | 461 | 15,944 | 15,129 |
CG Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CG Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
CG Oncology Comparisons
Industry
Financing
Details
CG Oncology Competitors (41)
One of CG Oncology’s 41 competitors is Oncorus, a Formerly VC-backed company based in Andover, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oncorus | Formerly VC-backed | Andover, MA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA |
CG Oncology Patents
CG Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220331384-A1 | Methods of treating bladder cancer | Active | 14-Apr-2017 | ||
| US-11596660-B2 | Methods of treating bladder cancer | Active | 14-Apr-2017 | ||
| JP-2022164776-A | How to treat bladder cancer | Active | 14-Apr-2017 | ||
| US-11338003-B2 | Methods of treating bladder cancer with an oncolytic virus | Active | 14-Apr-2017 | ||
| EP-3610026-A1 | Methods of treating bladder cancer | Pending | 14-Apr-2017 | A61P13/10 |
CG Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CG Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CG Oncology ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
CG Oncology FAQs
-
When was CG Oncology founded?
CG Oncology was founded in 2010.
-
Where is CG Oncology headquartered?
CG Oncology is headquartered in Irvine, CA.
-
What is the size of CG Oncology?
CG Oncology has 61 total employees.
-
What industry is CG Oncology in?
CG Oncology’s primary industry is Drug Discovery.
-
Is CG Oncology a private or public company?
CG Oncology is a Public company.
-
What is CG Oncology’s stock symbol?
The ticker symbol for CG Oncology is CGON.
-
What is the current stock price of CG Oncology?
As of 17-Jan-2025 the stock price of CG Oncology is $29.08.
-
What is the current market cap of CG Oncology?
The current market capitalization of CG Oncology is $2.21B.
-
What is CG Oncology’s current revenue?
The trailing twelve month revenue for CG Oncology is $684K.
-
Who are CG Oncology’s competitors?
Oncorus, Renova Therapeutics, Adaptimmune Therapeutics, NexImmune, and SAGE Therapeutics are some of the 41 competitors of CG Oncology.
-
What is CG Oncology’s annual earnings per share (EPS)?
CG Oncology’s EPS for 12 months was -$15.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
